Medivation jumps on Xtandi sales

Medivation Inc. (NASDAQ:MDVN) jumped $6.71 (11%) to $66.57 on Friday after partner Astellas Pharma Inc. (Tokyo:4503) reported sales of prostate cancer drug Xtandi enzalutamide of Y20.5 billion ($208.3 million) for the first half of its FY13, which covers April through September 2013. The figure includes Y17.7 billion ($179.8 million) in U.S. sales. Astellas said it now expects Y39.7 billion ($403.4 million) in worldwide Xtandi sales for its full FY13, which ends March 31, 2014. ...